Qiming Venture Partners and Its Investors Named to 36Kr Annual China Top 10 Track Industry Investment Institution Lists
Technology is reconnecting industries. This list documents the venture capital forces taking part, the investors behind them, and the depth each has reached.
36Kr has released its 2026 Industry Investment Institution Rankings across ten major sectors. Qiming Venture Partners was named to the TOP30 for China's advanced manufacturing, embodied artificial intelligence, and artificial intelligence sectors, as well as the TOP20 for life sciences.
Alex Zhou, Managing Partner at Qiming Venture Partners, was selected for the TOP30 China Embodied AI Investors and TOP30 China AI Investors. William Hu, Managing Partner at Qiming Venture Partners, was selected for the TOP20 China Life Sciences Investors.
Qiming Venture Partners
Named to
China Advanced Manufacturing Investment Institutions TOP30
China Embodied Artificial Intelligence Investment Institutions TOP30
China Artificial Intelligence Investment Institutions TOP30
China Life Sciences Investment Institutions TOP20
Alex Zhou, Managing Partner, Qiming Venture Partners
Selected for
China Embodied Artificial Intelligence Investors TOP30
China Artificial Intelligence Investors TOP30
William Hu, Managing Partner, Qiming Venture Partners
Selected for
China Life Sciences Investors TOP20
36Kr noted that this year's evaluation combined online surveys with offline interviews, using fundraising, investment, portfolio management, and exit data as its foundation while also weighing industrial落地, technology enablement, and exit performance to assess investment practices across different sectors. Scale and deal count form part of the record, but an institution's ability to grasp the specific challenges of an industry also determines the quality of its investments. The AI and embodied AI TOP30 lists share 19 overlapping institutions — an intersection of over 60% that points to an emerging technical convergence. As large models extend into the physical world, robots are needed to carry perception and action, while chips, materials, and precision manufacturing provide underlying support. A seemingly independent new track often connects to accumulated capabilities across multiple industries, and investors' research horizons are expanding beyond their original sector boundaries in response. Technology is reconnecting industries, and these rankings document the venture capital forces participating in this shift, the investors behind them, and the depth each has reached.
Source | 36Kr**
Past Coverage
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, Qiming has focused on investing in outstanding early- and growth-stage companies in technology and healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), APT Medical (688617.SH), Sanyou Medical (688085.SH), AmoyDx (300685.SZ), Sinocelltech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, Leads Biolabs, and StepFun.